Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: Economic analysis of the SPLINT trial

Diabetes Care

Volumn 28, Issue 1, 2005, Pages 40-46

  Mason, James M ^a   Freemantle, Nick ^b   Gibson, J Martin ^c   New, John P ^c  

^a DURHAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL;

ARTICLE; BEHAVIOR; BLOOD PRESSURE REGULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOSPITAL CARE; HYPERLIPIDEMIA; HYPERTENSION; NURSE; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR;

BLOOD GLUCOSE; BLOOD PRESSURE; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENGLAND; HEALTH POLICY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; SPECIALTIES, NURSING;

EID: 11844296652     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.1.40     Document Type: Article

References (23)

1. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
2. UK Prospective Diabetes Study Group: Efficacy of atenolol and captropril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-720, 1998
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23-33, 2002
4. Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M: When is it cost-effective to change the behaviour of health professionals? J Am Med Assoc 286: 2988-2992, 2001
5. New JP, Mason JM, Freemantle N, Teasdale S, Wong L, Burns JA, Gibson JM: Specialist nurse-led intervention to treat and control hypertension and hyperlipidaemia in diabetes (SPLINT): a randomised controlled trial. Diabetes Care 26:2250-2255, 2003
6. New JP, Hollis S, Campbell F, McDowell D, Burns E, Dornan TL, Young RJ: Measuring clinical performance and outcomes from diabetes information systems: an observational study. Diabetologia 43:836-843, 2000
7. UK Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 317:720-726, 1998
8. CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
9. Grover SA, Coupai L, Zowall H, Dorais M: Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 102:722-727, 2000
10. CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
11. Wilson PWF, D'Agostino RBD, Levy D, Belanger AM, Silbershaltz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847, 1998
12. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312-318, 1991
13. Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 121:293-298, 1991
14. Kannel WB, Wolf PA, Garrison RJ (Eds.): Survival following initial cardiovascular events: 30 year follow-up. In The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Springfield, IL, U.S. Department of Commerce, National Technical Information Service, 1988
15. Office for National Statistics: Mortality Statistics Cause Review of the Registrar General on Deaths by Cause, Sex and Age, in England & Wales 2000. London, National Statistics, Series DH2, no. 27, 2001
16. Netten A, Curtis L: Unit Costs of Health and Social Care 2002. Personal Social Services Research Unit, University of Kent at Canterbury. http://www.ukc.ac.uk/PSSRU
17. Department of Health: Prescription Cost Analysis: England 2002. http://www.doh.gov.uk/stats/pca2002.htm
18. Department of Health: Reference Costs: England 2001. http://www.doh.gov. uk/nhsexec/refcosts2001.htm
19. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ: Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making 22:290-308, 2002
20. Owens DK: Interpretation of cost-effectiveness analysis. J Gen Intern Med 13:716-717, 1998
21. Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E: A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA 283:2816-2821, 2000
22. Hulscher MEJL, Wensing M, van der Weijden T, Grol R: Interventions to implement prevention in primary care (Cochrane Review). In The Cochrane Library. Issue 3. Oxford, U.K., Update Software, 2003
23. New JP, Mason JM, Freemantle N, Teasdale S, Wong L, Bruce NJ, Burns JA, Gibson JM: Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomised controlled trial. Diabet Med 21:599-603, 2004